These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24796963)

  • 1. Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; de Lourdes Chauffaille M; Chiattone CS; Lima AS; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Br J Haematol; 2014 Aug; 166(4):540-9. PubMed ID: 24796963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study.
    Imaizumi M; Tawa A; Hanada R; Tsuchida M; Tabuchi K; Kigasawa H; Kobayashi R; Morimoto A; Nakayama H; Hamamoto K; Kudo K; Yabe H; Horibe K; Tsuchiya S; Tsukimoto I
    Br J Haematol; 2011 Jan; 152(1):89-98. PubMed ID: 20735397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL.
    Testi AM; Pession A; Diverio D; Grimwade D; Gibson B; de Azevedo AC; Moran L; Leverger G; Elitzur S; Hasle H; van der Werff ten Bosch J; Smith O; De Rosa M; Piciocchi A; Lo Coco F; Foà R; Locatelli F; Kaspers GJL
    Blood; 2018 Jul; 132(4):405-412. PubMed ID: 29789356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
    Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
    Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
    Sanz MA; Montesinos P; Kim HT; Ruiz-Argüelles GJ; Undurraga MS; Uriarte MR; Martínez L; Jacomo RH; Gutiérrez-Aguirre H; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Vellenga E; Holowiecka A; González-Huerta AJ; Fernández P; De la Serna J; Brunet S; De Lisa E; González-Campos J; Ribera JM; Krsnik I; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Rego EM;
    Ann Hematol; 2015 Aug; 94(8):1347-56. PubMed ID: 25975975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
    Montesinos P; Rayón C; Vellenga E; Brunet S; González J; González M; Holowiecka A; Esteve J; Bergua J; González JD; Rivas C; Tormo M; Rubio V; Bueno J; Manso F; Milone G; de la Serna J; Pérez I; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA; ;
    Blood; 2011 Feb; 117(6):1799-805. PubMed ID: 21148082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.
    Sobas M; Montesinos P; Boluda B; Bernal T; Vellenga E; Nomdedeu J; González-Campos J; Chillón M; Holowiecka A; Esteve J; Bergua J; González-Sanmiguel JD; Gil-Cortes C; Tormo M; Salamero O; Manso F; Fernández I; de la Serna J; Moreno MJ; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA;
    Leuk Lymphoma; 2019 Apr; 60(4):1030-1035. PubMed ID: 30322324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
    Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
    J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
    Xu LW; Su YZ; Tao HF
    Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
    Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
    Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All trans retinoic acid in acute promyelocytic leukemia.
    Degos L; Wang ZY
    Oncogene; 2001 Oct; 20(49):7140-5. PubMed ID: 11704842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group.
    Takahashi H; Watanabe T; Kinoshita A; Yuza Y; Moritake H; Terui K; Iwamoto S; Nakayama H; Shimada A; Kudo K; Taki T; Yabe M; Matsushita H; Yamashita Y; Koike K; Ogawa A; Kosaka Y; Tomizawa D; Taga T; Saito AM; Horibe K; Nakahata T; Miyachi H; Tawa A; Adachi S
    Br J Haematol; 2016 Aug; 174(3):437-43. PubMed ID: 27029412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia.
    Lucena-Araujo AR; Coelho-Silva JL; Pereira-Martins DA; Silveira DR; Koury LC; Melo RAM; Bittencourt R; Pagnano K; Pasquini R; Nunes EC; Fagundes EM; Gloria AB; Kerbauy F; de Lourdes Chauffaille M; Bendit I; Rocha V; Keating A; Tallman MS; Ribeiro RC; Dillon R; Ganser A; Löwenberg B; Valk PJM; Lo-Coco F; Sanz MA; Berliner N; Rego EM
    Blood; 2019 Sep; 134(12):951-959. PubMed ID: 31292112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy.
    Montesinos P; González JD; González J; Rayón C; de Lisa E; Amigo ML; Ossenkoppele GJ; Peñarrubia MJ; Pérez-Encinas M; Bergua J; Debén G; Sayas MJ; de la Serna J; Ribera JM; Bueno J; Milone G; Rivas C; Brunet S; Löwenberg B; Sanz M
    J Clin Oncol; 2010 Aug; 28(24):3872-9. PubMed ID: 20625122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).
    Gupta V; Yi QL; Brandwein J; Lipton JH; Messner HA; Schuh AC; Wells RA; Minden MD
    Leuk Res; 2005 Jan; 29(1):113-4. PubMed ID: 15541484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.